
APPENDIX A

- 123. An isolated polypeptide of any one of claims 202-203 which is a recombinant polypeptide.
- 132. A fusion protein comprising a polypeptide of any one of claims 202-203 and an additional amino acid sequence.
- 133. A fusion protein of claim 132, wherein the additional amino acid sequence comprises an *H. pylori* polypeptide.
- 149. A composition comprising a polypeptide of any one of claims 202-203 and a pharmaceutically acceptable carrier.
- 202. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- 203. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO: 809.
- 212. A composition comprising a fusion protein of claim 132 and a pharmaceutically acceptable carrier.
- 220. An isolated polypeptide of any one of claims 202-203 comprising at least about 12 consecutive amino acid residues of SEQ ID NO: 809.
- 221. An isolated polypeptide of any one of claims 202-203 comprising at least about 16 consecutive amino acid residues of SEQ ID NO: 809.

U.S. Serial No.: 08/487,032

Group Art Unit: 1645

- 222. An isolated polypeptide of any one of claims 202-203 comprising at least about 20 consecutive amino acid residues of SEQ ID NO: 809.
- 223. An isolated polypeptide of any one of claims 202-203 comprising at least about 50 consecutive amino acid residues of SEQ ID NO: 809.
- 224. An isolated polypeptide of any one of claims 202-203 comprising at least about 100 consecutive amino acid residues of SEQ ID NO: 809.
- 225. (New) An isolated polypeptide consisting of at least 10 consecutive amino acid residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- 226. (New) An isolated polypeptide consisting of at least 10 consecutive amino acid residues of SEQ ID NO: 809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO: 809.
- 227. (New) An isolated polypeptide of any one of claims 225-226 which is a recombinant polypeptide.
- 228. (New) A fusion protein comprising a polypeptide of any one of claims 225-226 and an additional amino acid sequence.
- 229. (New) A fusion protein of claim 228, wherein the additional amino acid sequence comprises an *H. pylori* polypeptide.
- 230. (New) A composition comprising a polypeptide of any one of claims 225-226 and a pharmaceutically acceptable carrier.



- 231. (New) A composition comprising a fusion protein of claim 228 and a pharmaceutically acceptable carrier.
- 232. (New) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809 and no more than 148 amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:809.
- 233. (New) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 809 and no more than 148 amino acid residues of SEQ ID NO:809, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO: 809.
- 234. **(New)** An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO:809, which encodes an antigenic determinant.
- 235. (New) An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO:809, which encodes an epitope.